AV Favipiravir
(Die Seite wurde neu angelegt: „ {{tp|p=32401463|t=2006. Favipiravir|pdf=|usr=007}} {{tp|p=32346491|t=ä. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study |pd…“) |
|||
| Zeile 7: | Zeile 7: | ||
{{tp|p=32475019|t=2020. Pharmacokinetics of Favipiravir in Critically Ill Patients with COVID-19.|pdf=|usr=007}} | {{tp|p=32475019|t=2020. Pharmacokinetics of Favipiravir in Critically Ill Patients with COVID-19.|pdf=|usr=007}} | ||
{{tp|p=32417899|t=2020. Favipiravir, an antiviral for COVID-19?|pdf=|usr=008}} | {{tp|p=32417899|t=2020. Favipiravir, an antiviral for COVID-19?|pdf=|usr=008}} | ||
| + | {{tp|p=32585765|t=2020. A Case of Successful Treatment of Severe COVID-19 Pneumonia with Favipiravir and Tocilizumab in Post-kidney Transplant Recipient.|pdf=|usr=010}} | ||
| + | {{tp|p=32536670|t=2020. Uric Acid Elevation by Favipiravir, an Antiviral Drug.|pdf=|usr=011}} | ||
| + | |||
| + | |||
| + | {{tp|p=32353191|t=2020. Response to "Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2".|pdf=|usr=011}} | ||
Version vom 7. Juli 2020, 12:00 Uhr
32401463 2006. Favipiravir
32346491 ä. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
32246834 2020. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection
32350860 2020. Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2
32360327 ä. Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidence
32475019 2020. Pharmacokinetics of Favipiravir in Critically Ill Patients with COVID-19.
32417899 2020. Favipiravir, an antiviral for COVID-19?
32585765 2020. A Case of Successful Treatment of Severe COVID-19 Pneumonia with Favipiravir and Tocilizumab in Post-kidney Transplant Recipient.
32536670 2020. Uric Acid Elevation by Favipiravir, an Antiviral Drug.
32353191 2020. Response to "Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2".
